<SEC-DOCUMENT>0001193125-26-332742.txt : 20260804
<SEC-HEADER>0001193125-26-332742.hdr.sgml : 20260804
<ACCEPTANCE-DATETIME>20260804160307
ACCESSION NUMBER:		0001193125-26-332742
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20260731
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260804
DATE AS OF CHANGE:		20260804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Seres Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001609809
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				274326290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37465
		FILM NUMBER:		261238421

	BUSINESS ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617 945 9626

	MAIL ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Seres Health, Inc.
		DATE OF NAME CHANGE:	20140603
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d133274d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mcrb="http://serestherapeutics.com/20260731" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-324">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-07-31_to_2026-07-31">0001609809</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="mcrb-20260731.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-07-31_to_2026-07-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001609809</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-07-31</xbrli:startDate> <xbrli:endDate>2026-07-31</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-335">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-07-31_to_2026-07-31" format="ixt:datemonthdayyearen" id="ixv-336">July&#160;31, 2026</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-337">SERES THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-07-31_to_2026-07-31" format="ixt-sec:stateprovnameen" id="ixv-338">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-339">001-37465</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-340">27-4326290</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-341">101 Cambridgepark Drive</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-342">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-343">MA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-344">02140</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-345">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-346">945-9626</ix:nonNumeric></span></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-07-31_to_2026-07-31" format="ixt-sec:boolballotbox" id="ixv-347">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-07-31_to_2026-07-31" format="ixt-sec:boolballotbox" id="ixv-348">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-07-31_to_2026-07-31" format="ixt-sec:boolballotbox" id="ixv-349">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-07-31_to_2026-07-31" format="ixt-sec:boolballotbox" id="ixv-350">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-351">Common stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-352">MCRB</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-07-31_to_2026-07-31" format="ixt-sec:exchnameen" id="ixv-353">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-07-31_to_2026-07-31" format="ixt-sec:boolballotbox" id="ixv-354">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Lease Amendment and Termination Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;31, 2026 (the &#8220;Execution Date&#8221;), Seres Therapeutics, Inc. (the &#8220;Company&#8221;) entered into the Third Amendment to Lease and Termination Agreement (the &#8220;Termination Agreement&#8221;) with <span style="white-space:nowrap">BMR-Sidney</span> Research Campus LLC, a Delaware limited liability company (the &#8220;Sidney Street Landlord&#8221;), the purpose of which is to effect an early termination of one of the Company&#8217;s leases, reducing the Company&#8217;s ongoing annual facilities costs and materially eliminating the Company&#8217;s primary restoration obligations. The Termination Agreement amends the Lease Agreement, dated November&#160;11, 2015, by and between the Company and the Sidney Street Landlord (as amended, the &#8220;Lease&#8221;), pursuant to which the Company leases approximately 68,636 rentable square feet of office, laboratory, and manufacturing space located at 200 Sidney Street, Cambridge, Massachusetts (the &#8220;Existing Premises&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Termination Agreement provides for (i)&#160;effective as of August&#160;1, 2026, the surrender by the Company to the Landlord of an aggregate area of approximately 21,295 rentable square feet of the Existing Premises (the &#8220;Early Termination Premises&#8221;) and (ii)&#160;the revision of the expiration date of the term of the Lease with respect to the remaining 47,341 rentable square feet of the Existing Premises (the &#8220;Renewal Premises&#8221;) from January&#160;13, 2031 to December&#160;31, 2026. As consideration for the Termination Agreement, the Company agreed to pay the following: (i)&#160;an increase to the letter of credit held by the Sidney Street Landlord in the amount of approximately $2.2&#160;million (for a total letter of credit of approximately $3.6 million), which the Sidney Street Landlord will apply toward rent and operating expenses through the term of the Renewal Premises, (ii)&#160;on or before January&#160;4, 2027, a deferred payment of $3.85&#160;million, representing an additional termination payment, and (iii)&#160;an equity issuance of shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), valued at approximately $0.5&#160;million (the &#8220;Share Issuance&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Issuance Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;31, 2026, in connection with the Share Issuance, the Company entered into a Stock Issuance Agreement (the &#8220;Stock Issuance Agreement&#8221;) with the Sidney Street Landlord, pursuant to which the Company agreed to issue 103,520 shares of Common Stock (the &#8220;Shares&#8221;) to the Sidney Street Landlord at a price per share of $4.83, which was the closing price of the Common Stock on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) on July&#160;31, 2026, for a total value of $500,001.60. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares are to be issued no later than five business days after the Execution Date. The Shares are registered under the Company&#8217;s registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-273794),</span> pursuant to a prospectus supplement, dated July&#160;31, 2026 and the accompanying base prospectus, dated August&#160;15, 2023, and will be freely tradeable when issued. In the event the value of the Shares on the date of issuance (calculated using the closing price on Nasdaq on such date) (the &#8220;Issuance Date Value&#8221;) is less than $500,000, the Company is obligated to pay to the Sidney Street Landlord, in cash, the difference between $500,000 and the Issuance Date Value. The Stock Issuance Agreement contains customary representations and warranties of the Company and the Sidney Street Landlord and customary conditions to the share issuance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Stock Issuance Agreement does not purport to be complete and is qualified in its entirety by reference to the Stock Issuance Agreement, a copy of which is attached as Exhibit 10.2 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the opinion of Latham&#160;&amp; Watkins LLP relating to the validity of the Shares is filed herewith as Exhibit 5.1. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.02.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Termination of a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth under the heading &#8220;Lease Amendment and Termination Agreement&#8221; in Item 1.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> is incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d133274dex101.htm">Third Amendment to Lease and Termination Agreement, dated July&#160;31, 2026, by and between Seres Therapeutics, Inc. and <span style="white-space:nowrap">BMR-Sidney</span> Research Campus, LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d133274dex102.htm">Stock Issuance Agreement, dated July&#160;31, 2026, by and between Seres Therapeutics, Inc. and <span style="white-space:nowrap">BMR-Sidney</span> Research Campus, LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d133274dex51.htm">Opinion of Latham&#160;&amp; Watkins LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d133274dex51.htm">Consent of Latham&#160;&amp; Watkins LLP (included in Exhibit 5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation <span style="white-space:nowrap">S-K.</span> The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">SERES THERAPEUTICS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: August&#160;4, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. DesRosier</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Thomas J. DesRosier</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and Chief Legal Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d133274dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Clarendon Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston,
Massachusetts 02116</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +1.617.948.6000 Fax: +1.617.948.6001</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.lw.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g133274g0804031743525.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">FIRM / AFFILIATE OFFICES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Austin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Milan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Beijing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Munich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Boston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brussels</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Orange County</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">August&nbsp;4, 2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chicago</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paris</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dubai</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Riyadh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">D&uuml;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Francisco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seoul</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Silicon Valley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Houston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">London</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tel Aviv</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Seres Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Los Angeles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tokyo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">101 Cambridgepark Drive</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Madrid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Washington, D.C.</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts 02140 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: <U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (Registration
No.</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;333-273794)</FONT></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressee set forth above: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as special counsel to Seres Therapeutics, Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), in connection
with the proposed issuance of 103,520 shares of common stock, $0.001 par value per share (the &#8220;<B><I>Shares</I></B>&#8221;). The Shares are included in a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the
Securities Act of 1933, as amended (the &#8220;<B><I>Act</I></B>&#8221;), filed with the Securities and Exchange Commission (the &#8220;<B><I>Commission</I></B>&#8221;) on August&nbsp;8, 2023 (Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-273794),</FONT> as amended (the &#8220;<B><I>Registration Statement</I></B>&#8221;), and are being offered pursuant to a base prospectus dated August&nbsp;15, 2023 (the &#8220;<B><I>Base
Prospectus</I></B>&#8221;), a prospectus supplement dated July&nbsp;31, 2026 filed with the Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the &#8220;<B><I>Prospectus</I></B>&#8221;). The Shares are being issued
pursuant to a Stock Issuance Agreement, dated July&nbsp;31, 2026, between the Company and <FONT STYLE="white-space:nowrap">BMR-Sidney</FONT> Research Campus LLC (the &#8220;<B><I>Stock Issuance Agreement</I></B>&#8221;). This opinion is being
furnished in connection with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or
related prospectus, other than as expressly stated herein with respect to the issue of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined such
matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having
independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware and we express no opinion with respect to any other laws. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>August 4, 2026 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Page 2 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g133274g0804031744665.jpg" ALT="LOGO" STYLE="width:1.73333in;height:0.127083in;">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as
of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par
value) in the circumstances contemplated by the Stock Issuance Agreement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and
nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company&#8217;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated August&nbsp;4, 2026 and to the reference to our firm in the
prospectus under the heading &#8220;Legal Matters.&#8221; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission
thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sincerely,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Latham&nbsp;&amp; Watkins LLP</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d133274dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDMENT TO LEASE AND TERMINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS THIRD AMENDMENT TO LEASE AND TERMINATION AGREEMENT (this &#8220;<U>Agreement</U>&#8221;) is entered into as of this 31st day of July,
2026 (&#8220;<U>Execution Date</U>&#8221;), by and between <FONT STYLE="white-space:nowrap">BMR-SIDNEY</FONT> RESEARCH CAMPUS LLC, a Delaware limited liability company (&#8220;<U>Landlord</U>&#8221;), and SERES THERAPEUTICS, INC., a Delaware
corporation (&#8220;<U>Tenant</U>&#8221;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. WHEREAS, Landlord and Tenant entered into that certain Lease dated as of November&nbsp;11, 2015, as amended by that certain First Amendment
to Lease dated as of December&nbsp;9, 2022, and that certain Second Amendment to Lease dated as of January&nbsp;25, 2024 (as the same may have been further amended, amended and restated, supplemented or otherwise modified from time to time, the
&#8220;Existing <U>Lease</U>&#8221;), whereby Tenant leases certain premises (the &#8220;<U>Premises</U>&#8221;) from Landlord in the building at 200 Sidney Street, Cambridge, Massachusetts (the &#8220;<U>Building</U>&#8221;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. WHEREAS, pursuant to that certain Sublease Agreement dated as of January&nbsp;25, 2024 by and between Tenant, as sublandlord, and AbbVie
Inc. (&#8220;<U>AbbVie</U>&#8221;), as subtenant, and that certain Consent to Sublease dated as of January&nbsp;25, 2024 by and between Landlord, Tenant and AbbVie (as the same may have been further amended or modified from time to time, the
&#8220;<U>AbbVie Sublease</U>&#8221;), AbbVie currently subleases (i)&nbsp;approximately 10,892 rentable square feet on the first (1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>) floor of the Building, and (ii)&nbsp;approximately 10,403
rentable square feet on the fourth (4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) floor of the Building, as shown on <U>Exhibit A</U> attached hereto and incorporated herein (the &#8220;<U>First and Fourth Floor Surrender
Premises</U>&#8221;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. WHEREAS, Landlord and Tenant desire to (i)&nbsp;partially terminate the Existing Lease with respect to the
First and Fourth Floor Surrender Premises effective upon the Execution Date, and (ii)&nbsp;terminate the Existing Lease with respect to the remaining portion of the Premises consisting of approximately 47,341 rentable square feet, as shown on
<U>Exhibit B</U> attached hereto and incorporated herein (collectively, the &#8220;<U>Remaining Premises</U>&#8221;) effective as of December&nbsp;31, 2026, in each case in accordance with the following conditions and provisions; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For purposes of this Amendment, capitalized terms shall have the meanings ascribed to them in the Existing
Lease unless otherwise defined herein. The Existing Lease, as amended by this Amendment, is referred to collectively herein as the &#8220;<U>Lease</U>.&#8221; From and after the date hereof, the term &#8220;Lease,&#8221; as used in the Existing
Lease, shall mean the Existing Lease, as amended by this Amendment. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Partial Termination &#8211; First and Fourth Floor Sublease Premises</U>. Effective
upon the Execution Date, the Lease is hereby partially terminated with respect to the First and Fourth Floor Surrender Premises only. Notwithstanding anything to the contrary set forth in the Existing Lease, due to the Abbvie Sublease, Tenant shall
be relieved of Tenant&#8217;s surrender and decontamination obligations set forth in the Existing Lease, including those requirements set forth in <U>Section</U><U></U><U>&nbsp;26</U> of the Existing Lease, in connection with the First and Fourth
Floor Surrender Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Remaining Premises</U><I>. </I>From and after the Execution Date, the term &#8220;<U>Premises</U>,&#8221;
as used in the Lease, shall mean the Remaining Premises. The table set forth in <U>Section</U><U></U><U>&nbsp;2.2</U> of the Existing Lease is hereby deleted and replaced with the following, effective as the Execution Date: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Definition or Provision</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Means the Following (As of the
Execution Date)</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Approximate Rentable Area of Premises</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">47,341 square feet, consisting of 14,958 square feet on the basement floor of the Building, 31,375 square feet on the first (1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>) floor of the Building and 1,008
square feet on the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>) floor of the Building</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Approximate Rentable Area of Building</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">188,616 square feet</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Tenant&#8217;s Pro Rata Share of Building</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">25.10%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Rent</U>. From and after August&nbsp;1, 2026 (the &#8220;<U>Effective Date</U>&#8221;), monthly Rent
(including Base Rent, Tenant&#8217;s Adjusted Share of Operating Expenses, and Additional Rent) for the Remaining Premises shall be in the amount of $727,683.17 and shall be payable as set forth in Section&nbsp;6(a) of this Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Parking</U>. Effective as of the Execution Date, the parking spaces in the Parking Garage allocated to Tenant in accordance with the
Existing Lease shall be reduced from sixty-eight (68)&nbsp;parking spaces to zero (0)&nbsp;parking spaces. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Payments</U>. Pursuant
to this Amendment, the total monetary consideration payable by Tenant to Landlord will consist solely of the following: (a)&nbsp;an increase to the Letter of Credit in the amount of $2,238,415.84 (for a total Letter of Credit of $3,638,415.84),
which Landlord will apply toward Base Rent, Additional Rent, and Operating Expenses through the Expiration Date; (b)&nbsp;a Termination Fee of $3,850,000.00, payable by wire transfer no later than January&nbsp;4, 2027; and (c)&nbsp;an Equity
Issuance of shares of Seres common stock valued at $500,000.00, to be issued no later than five (5)&nbsp;business days after the Execution Date.<B></B><B>&nbsp;</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Letter of Credit Increase</U>. On or prior to the Execution Date, Tenant has arranged
for the Letter of Credit held by Landlord to be increased by Two Million Two Hundred Thirty-Eight Thousand Four Hundred Fifteen and 84/100 Dollars ($2,238,415.84), for a total Letter of Credit amount of Three Million Six Hundred Thirty-Eight
Thousand Four Hundred Fifteen and 84/100 Dollars ($3,638,415.84) (as so increased, the &#8220;<U>Letter of Credit</U>&#8221;). Landlord shall apply the Letter of Credit toward Annual Base Rent, Additional Rent (including Tenant&#8217;s Adjusted
Share of Operating Expenses), and all other amounts payable by Tenant under the Lease for each month through the Expiration Date. Landlord acknowledges that the amounts payable from the Letter of Credit shall constitute full and final payment of all
Base Rent, Additional Rent and Operating Expenses owing under the Lease through the Expiration Date, and there shall be no reconciliation of any Rent amounts, including Tenant&#8217;s Adjusted Share of Operating Expenses following the Expiration
Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination Fee</U>. No later than January&nbsp;4, 2027, Tenant shall pay to Landlord, by wire transfer in immediately
available funds, a termination fee equal to Three Million Eight Hundred Fifty Thousand and 00/100 Dollars ($3,850,000.00), as a fee and not a penalty (the &#8220;<U>Termination Fee</U>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Equity Issuance</U>. <U>Equity Issuance</U>.&nbsp;No later than five (5)&nbsp;business days after the Execution Date, Tenant shall
issue to Landlord (or Landlord&#8217;s designee) shares of Tenant&#8217;s common stock (the &#8220;<U>Shares</U>&#8221;) with a value equal to Five Hundred Thousand and 00/100 Dollars ($500,000.00).&nbsp;The number of Shares to be issued shall be
determined in accordance with the methodology set forth in the Stock Issuance Agreement in the form attached hereto as <U>Exhibit C</U> (the &#8220;<U>Equity Agreement</U>&#8221;), which Equity Agreement shall govern the calculation and issuance of
the Shares and shall be executed by the parties concurrently with this Amendment.&nbsp;The Shares shall be issued pursuant to Tenant&#8217;s effective registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (file no. <FONT
STYLE="white-space:nowrap">333-273794)</FONT> and shall be freely tradeable upon issuance without restriction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Remaining Premises
Obligations</U>. Except as set forth in this Amendment, Tenant shall remain responsible for the timely performance of all <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations of Tenant under the Lease with respect to the Remaining
Premises through the Expiration Date. For the avoidance of doubt, Tenant shall be responsible for paying any utilities for which it has contracted directly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary in the Lease, including without limitation <U>Sections 17.7</U>, <U>17.8</U>, <U>18.2</U>, and
<U>26.2</U> of the Existing Lease, Tenant shall have no obligation to remove or restore any Alterations, Tenant Improvements, fixtures, or other improvements existing in the Remaining Premises as of the Execution Date, and Tenant may surrender the
Remaining Premises with such Alterations, Tenant Improvements, fixtures, and other improvements in place, subject only to Tenant&#8217;s completion of the Turnover Requirements set forth on <U>Exhibit D</U> and Tenant&#8217;s other obligations under
this <U>Section</U><U></U><U>&nbsp;7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing, in the event Tenant completes the surrender requirements
under the Lease (including the Exit Survey) together with the requirements set forth on <U>Exhibit D</U> (collectively, the &#8220;<U>Turnover Requirements</U>&#8221;) with respect to the Remaining Premises prior to the Expiration Date, Landlord
agrees to perform Tenant&#8217;s repair and maintenance obligations under the Lease commencing on the date that Landlord has accepted Tenant&#8217;s completion of the Turnover Requirements (the &#8220;<U>Turnover Date</U>&#8221;). Tenant shall not
be liable for performing any repair and maintenance obligations following the Turnover Date; <U>provided</U>, however, that Tenant shall be liable for any costs related to damage arising from Tenant&#8217;s use or occupancy following the Turnover
Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary set forth in the Lease, (i)&nbsp;prior to the
Turnover Date, Landlord shall have the right to enter the Remaining Premises at any time upon twenty-four (24)&nbsp;hours&#8217; prior notice (which may be oral or by email to the Tenant-designated representative) except during an emergency, in
which event no prior notice shall be required by Landlord; and (ii)&nbsp;following the Turnover Date, Landlord shall the right to enter the Remaining Premises at any time. Tenant shall provide Landlord with five (5)&nbsp;access cards and five
(5)&nbsp;physical keys to access all spaces within the Remaining Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Landlord shall indemnify, defend, and hold harmless
Tenant, its officers, directors, employees, and agents from and against any and all claims, liabilities, losses, costs, and expenses (including reasonable attorneys&#8217; fees) arising out of or resulting from Landlord&#8217;s entry into, use of,
or exercise of control over the Remaining Premises following the Turnover Date, except to the extent arising from any acts or omissions (including the negligence or willful misconduct) of Tenant or its employees, agents, or contractors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Surrender of Remaining Premises and Lease Termination</U>. Tenant shall surrender the Remaining Premises to Landlord with the Turnover
Requirements completed no later than December&nbsp;31, 2026 (&#8220;<U>Expiration Date</U>&#8221;). Provided that Tenant has fully satisfied all of its obligations set forth in <U>Sections 6(a)</U>, <U>6(c)</U> and <U>7</U> of this Amendment
(collectively, the &#8220;<U>Termination Obligations</U>&#8221;), then the Lease shall terminate effective as of 11:59 p.m. Eastern time on the Expiration Date (&#8220;<U>Lease Termination</U>&#8221;). As of the Lease Termination, the Lease shall be
fully and finally surrendered and terminated and shall no longer be of any force or effect, except for those provisions that, by their express terms, survive the expiration or earlier termination of the Lease, including without limitation,
Tenant&#8217;s obligations pursuant to <U>Section</U><U></U><U>&nbsp;6(b)</U> hereof. For the avoidance of doubt, the parties hereby agree to waive reconciliation of Tenant&#8217;s Adjusted Share of Operating Expenses following calendar year 2026.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Broker</U>. Tenant represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining
of this Amendment and agrees to reimburse, indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord, at Tenant&#8217;s sole cost and expense) and hold harmless the Landlord Indemnitees for, from and
against any and all cost or liability for compensation claimed by any such broker or agent employed or engaged by it or claiming to have been employed or engaged by it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>No Default</U>. Tenant represents, warrants and covenants that, to the best of Tenant&#8217;s knowledge, Landlord and Tenant are not in
default of any of their respective obligations under the Existing Lease and no event has occurred that, with the passage of time or the giving of notice (or both) would constitute a default by either Landlord or Tenant thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Tenant confirms that, notwithstanding anything in the Lease to the
contrary, notices delivered to Tenant pursuant to the Lease should be sent to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Seres Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">101 Cambridgepark Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02140 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">ATTN: Legal
Department </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy to [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Effect of Amendment</U>. Except as modified by this Amendment, the Existing Lease and all the covenants, agreements, terms, provisions
and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. In the event of any conflict between the terms contained in this Amendment and the Existing Lease, the terms herein contained shall supersede and
control the obligations and liabilities of the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Successors and Assigns</U>. Each of the covenants, conditions and
agreements contained in this Amendment shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors, assigns and
sublessees. Nothing in this section shall in any way alter the provisions of the Lease restricting assignment and subletting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.
<U>Miscellaneous</U>. This Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Amendment are inserted and included solely for convenience and shall not
be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for
a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Authority</U>. Tenant guarantees, warrants and represents that the execution and consummation of this Amendment have been duly
authorized by all appropriate company action, and the individual or individuals signing this Amendment have the power, authority and legal capacity to sign this Amendment on behalf of and to bind all entities, corporations, partnerships, limited
liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.
<U>Counterparts; Facsimile and PDF Signatures</U>. This Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. A facsimile or portable document format (PDF) signature on
this Amendment shall be equivalent to, and have the same force and effect as, an original signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Representation of
Parties</U>. Each party represents that it has not made any assignment, sublease, transfer, conveyance or other disposition of the Lease or any interest therein, nor made or entered into any agreement that would result in any mechanic&#8217;s lien
or other claim, demand, obligation, liability, action or cause of action arising from or with respect to the Lease or the Premises, other than the Abbvie Sublease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Attorneys&#8217; Fees</U>. Except as otherwise expressly set forth in this Amendment,
each party shall pay its own costs and expenses incurred in connection with this Amendment and such party&#8217;s performance under this Amendment, provided, that if either party commences an action, proceeding, demand, claim, action, cause of
action or suit against the other party arising out of or in connection with this Amendment, then the substantially prevailing party shall be reimbursed by the other party for all reasonable costs and expenses, including reasonable attorneys&#8217;
fees and expenses, incurred by the substantially prevailing party in such action, proceeding, demand, claim, action, cause of action or suit, and in any appeal in connection therewith (regardless of whether the applicable action, proceeding, demand,
claim, action, cause of action, suit or appeal is voluntarily withdrawn or dismissed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Governing Law</U>. This Amendment shall be
governed by and construed and enforced in accordance with the laws of the Commonwealth of Massachusetts, without regard to the Commonwealth of Massachusetts&#8217; conflict of law principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Waiver of Jury Trial</U>. To the extent permitted by applicable laws, the parties waive trial by jury in any action, proceeding or
counterclaim brought by the other party hereto related to matters arising out of or in any way connected with this Amendment, Tenant&#8217;s use or occupancy of the Premises or any claim of injury or damage related to this Amendment or the Premises.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amendment as a sealed Massachusetts
instrument as of the day hereinabove first written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LANDLORD:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BMR-SIDNEY</FONT> RESEARCH CAMPUS LLC,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware limited liability company</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Colleen O&#8217;Connor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Colleen O&#8217;Connor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EVP, East Coast&nbsp;&amp; UK Marke</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TENANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SERES THERAPEUTICS, INC.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a
Delaware corporation</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Richard Kender</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Richard Kender</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Chairman and Interim CEO</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>d133274dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Copy </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCK ISSUANCE AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This STOCK ISSUANCE AGREEMENT (this &#8220;<U>Agreement</U>&#8221;) is made and entered into as of July&nbsp;31, 2026 by and between Seres
Therapeutics, Inc., a Delaware corporation (the &#8220;<U>Company</U>&#8221;), and <FONT STYLE="white-space:nowrap">BMR-SIDNEY</FONT> RESEARCH CAMPUS LLC, a Delaware limited liability company (the &#8220;<U>Landlord</U>&#8221;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. WHEREAS, the
Company and the Landlord have entered into a Third Amendment to Lease and Termination Agreement, dated on or about the date hereof (the &#8220;<U>Lease Termination Agreement</U>&#8221;), pursuant to which the Company and the Landlord have agreed to
terminate that certain Lease, dated as of November&nbsp;11, 2015, as amended, by and between the Company and the Landlord; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. WHEREAS,
pursuant to the Lease Termination Agreement, as part of the payment owed by the Company to the Landlord as set forth therein, the Company has agreed to issue to the Landlord the number of shares of the Company&#8217;s Common Stock, par value $0.001
per share (the &#8220;<U>Common Stock</U>&#8221;), with a value equal to approximately $500,000.00, and the number of such shares to be determined pursuant to Section&nbsp;2 hereof, which shares shall be freely tradeable upon issuance without
restriction; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. WHEREAS, the Company has filed the Registration Statement (as defined herein) with the Securities and Exchange
Commission (the &#8220;<U>SEC</U>&#8221;), in accordance with the provisions of the Securities Act of 1933, as amended (the &#8220;<U>1933 Act</U>&#8221;), and the applicable rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For the purposes of this Agreement, the
following terms shall have the meanings set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>1933 Act</U>&#8221; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>1934 Act</U>&#8221; means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Actions</U>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Affiliate</U>&#8221; means, with respect to any Person, any other Person which directly or indirectly through one or more
intermediaries Controls, is controlled by, or is under common Control with, such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Control</U>&#8221; (including the
terms &#8220;controlling&#8221;, &#8220;controlled by&#8221; or &#8220;under common control with&#8221;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether
through the ownership of voting securities, by contract or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Execution Date</U>&#8221; has the meaning set forth in the Lease Termination
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Material Adverse Effect</U>&#8221; means a material adverse effect on (i)&nbsp;the assets, liabilities, results of
operations, financial condition or business of the Company taken as a whole, (ii)&nbsp;the legality or enforceability of any of the Transaction Documents (as defined herein), (iii)&nbsp;the authority or ability of the Company to perform its
obligations under the Transaction Documents, including the issuance and delivery of the Shares as contemplated hereby, or (iv)&nbsp;the rights and remedies of the Landlord under the Transaction Documents; <I>provided</I>, <I>however</I>, that
(A)&nbsp;any change in the Company&#8217;s stock price or trading volume shall not, by itself, constitute a Material Adverse Effect, except that the underlying causes of such change may be taken into account in determining whether a Material Adverse
Effect has occurred, and (B)&nbsp;any adverse effect resulting solely from the announcement or pendency of the Lease Termination Agreement or this Agreement or the transactions contemplated thereunder or hereunder shall not, by itself, constitute a
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Material Contract</U>&#8221; means the contracts, instruments or other agreements that have been filed
as an exhibit to the SEC Documents pursuant to Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and that are material to the business of the Company as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Nasdaq</U>&#8221; means The Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Person</U>&#8221; means an individual, corporation, partnership, limited liability company, trust, business trust, association,
joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Proceeding</U>&#8221; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal
investigation or partial proceeding, such as a deposition), whether commenced or threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Prospectus</U>&#8221; means the
prospectus filed with the Registration Statement as supplemented by the Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Prospectus Supplement</U>&#8221;
means the prospectus supplement to the Prospectus complying with Rule 424(b) of the 1933 Act that is filed with the SEC under the Registration Statement setting forth the terms of the issuance of the Shares to the Landlord, the number of shares
being issued, the consideration therefor, and such other information as may be required under applicable rules and regulations of the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Registration Statement</U>&#8221; means the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-273794),</FONT> filed by the Company with the SEC, which registration statement is effective as of the date hereof, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>SEC Documents</U>&#8221; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.7</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Shares</U>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Share Issuance</U>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Share Issuance Date</U>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<U>Transaction Documents</U>&#8221; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Issuance of the Shares</U>. Upon the terms and subject to the conditions set forth herein,
the Company agrees to issue to the Landlord a number of shares of Common Stock equal to $500,000 divided by the closing price of a share of Common Stock on the Nasdaq on the Execution Date, rounded up to the nearest whole share (the
&#8220;<U>Shares</U>&#8221;), and the Landlord agrees to accept the Shares as payment under the Lease Termination Agreement (the &#8220;<U>Share Issuance</U>&#8221;), subject to the terms and conditions of this Agreement. The Share Issuance shall
occur no later than five business days after the Execution Date (the &#8220;<U>Share Issuance Date</U>&#8221;). The Shares shall be issued in book entry form and shall be freely tradeable upon issuance without restriction. Prior to the Share
Issuance, the Company shall file the Prospectus Supplement with the SEC. The Company shall provide the Landlord with a copy of the Prospectus Supplement for its review and comment not less than two (2)&nbsp;business days prior to the filing thereof
with the SEC, shall consider in good faith any comments of the Landlord thereon, and shall not file such Prospectus Supplement with the SEC without the Landlord&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if the product of (i)&nbsp;the number of Shares issued to the Landlord and (ii)&nbsp;the closing price of
the Common Stock on Nasdaq on the date the Shares are actually issued to the Landlord is less than $500,000.00,<B> </B>, then the Company shall pay to the Landlord, in cash, by wire transfer of immediately available funds, an amount equal to the
difference between (a) $500,000 and (b)&nbsp;the value of the Shares issued to the Landlord, calculated using the closing price of a share of Common Stock on Nasdaq on the date of actual issuance, such that the aggregate value of the Shares and such
cash payment received by the Landlord equals $500,000; provided, however, that the Company shall have no obligation to make such cash payment to the extent such shortfall results from a delay in the issuance of the Shares caused by the
Landlord&#8217;s failure to provide its consent as set forth in Section&nbsp;2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>.
The Company hereby represents and warrants to the Landlord as of the date hereof and the Share Issuance Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1. <U>Organization, Good
Standing and Qualification</U>. The Company is an entity duly incorporated, validly existing and in good standing under the laws of the State of Delaware, with the requisite corporate power and authority to own or lease and use its properties and
assets, to execute and deliver this Agreement, to carry out the provisions of this Agreement, to issue the Shares and to carry on its business as presently conducted as described in the SEC Documents. The Company is not in violation or default in
any material respect of any of the provisions of its certificate of incorporation or bylaws. The Company is duly qualified to do business as a foreign entity and is in good standing (to the extent such concept exists in the relevant jurisdiction) in
each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification necessary, except to the extent any failure to so qualify has not had and would not reasonably be expected to have a Material
Adverse Effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2. <U>Authorization</U>. The Company has the requisite corporate power and authority and
has taken all requisite corporate action necessary for, and no further action on the part of the Company, its officers, directors and stockholders is necessary for, (i)&nbsp;the authorization, execution and delivery of this Agreement, the Lease
Termination Agreement, and each of the other agreements to which it is a party or by which it is bound and which is entered into by the parties hereto in connection with the transactions contemplated hereby and thereby (collectively, the
&#8220;<U>Transaction Documents</U>&#8221;), (ii)&nbsp;the authorization of the performance of all obligations of the Company under the Transaction Documents, and (iii)&nbsp;the authorization, issuance and delivery of the Shares in accordance with
the terms hereof. Each of the Transaction Documents has been duly executed and delivered by the Company and, assuming due authorization, execution and delivery by the Landlord, if a party thereto, constitutes the valid and binding obligation of the
Company enforceable in accordance with its terms, except (a)&nbsp;as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors&#8217; rights, (b)&nbsp;general
principles of equity that restrict the availability of equitable remedies and (c)&nbsp;to the extent that the enforceability of indemnification provisions may be limited by applicable laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3. <U>Valid Issuance</U>. The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement and the
Lease Termination Agreement, will be validly issued, fully paid and nonassessable, and shall be free and clear of all security interests, liens, other encumbrances and restrictions (other than those created by the Landlord). The Shares, when issued
and delivered as contemplated hereby, will be issued pursuant to the Registration Statement and in accordance with applicable federal and state securities laws, and will be freely transferable by the Landlord under the 1933 Act. The issuance of the
Shares is not subject to any preemptive rights, rights of first refusal or other similar rights of any stockholder of the Company or other person. No holder of the Shares will be subject to personal liability solely by reason of being such a holder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4. <U>Consents</U>. The execution, delivery and performance by the Company of this Agreement and the issuance of the Shares require no
consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant to applicable state and
federal securities laws and the rules and regulations of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5. <U>No Conflict, Breach, Violation or Default</U>. The execution,
delivery and performance of this Agreement by the Company and the issuance of the Shares in accordance with the provisions thereof will not (i)&nbsp;conflict with or result in a breach or violation of (a)&nbsp;any of the terms and provisions of, or
constitute a default under, the Company&#8217;s Restated Certificate of Incorporation or Amended and Restated Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Landlord through the EDGAR
system), or (b)&nbsp;assuming the accuracy of the representations and warranties in <U>Section</U><U></U><U>&nbsp;4</U>, any applicable statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having
jurisdiction over the Company, or any of their assets or properties, or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would become a default) under, result in the creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of the Company or give to others any rights of
termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract except, in the case of clauses (i)(b) and (ii)&nbsp;only, for such conflicts, breaches, violations and defaults as have
not and would not reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.6. <U>Litigation</U>. Except as set forth in the SEC
Documents and as would not reasonably be expected to have a Material Adverse Effect, there is no action, suit, inquiry, notice of violation, proceeding or investigation (collectively, &#8220;<U>Actions</U>&#8221;) pending or, to the knowledge of the
Company, threatened against or affecting the Company, any subsidiary of the Company or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county,
local or foreign). None of the Actions set forth in the SEC Documents (i)&nbsp;adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Shares or (ii)&nbsp;could, if there were an
unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Except as would not reasonably be expected to have a Material Adverse Effect, neither the Company nor any of its subsidiaries, nor any director or officer
thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. Except as set forth in the SEC Documents and as has not had and would not
reasonably be expected to have a Material Adverse Effect, there has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company or any current or former director or officer
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7. <U>SEC Documents; Financial Statements</U>. Since January&nbsp;1, 2025, the Company has filed in a timely manner all
documents that the Company was required to file with the SEC under Sections 13, 14(a) and 15(d) of the 1934 Act (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus,
being collectively referred to herein as the &#8220;<U>SEC Documents</U>&#8221;). As of their respective filing dates (or, if amended prior to the date of this Agreement, when amended), each SEC Document complied as to form in all material respects
with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder. None of the SEC Documents as of their respective dates contained any untrue statement of material fact or omitted to state a material fact
required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading. The consolidated financial statements of the Company included in the SEC Documents present
fairly the financial condition, results of operations and cash flows of the Company on a consolidated basis as of the dates and for the periods indicated, complied as to form with the applicable accounting requirements of the 1934 Act and were
prepared in conformity with United States generally accepted accounting principles applied on a consistent basis throughout the periods involved (except as otherwise noted therein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.8. <U>Compliance with Nasdaq Continued Listing Requirements</U>. The Company is in compliance with applicable Nasdaq Stock Market, LLC
continued listing requirements. There are no proceedings pending or, to the Company&#8217;s knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of the
delisting of the Common Stock from Nasdaq. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.9. <U>Registration Statement</U>. The Company has prepared and filed the Registration
Statement in conformity with the requirements of the 1933 Act, which became effective on August&nbsp;15, 2023, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The
Registration Statement is effective under the 1933 Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the SEC and no proceedings for
that purpose have been instituted or, to the knowledge of the Company, are threatened by the SEC. The Company, if required by the rules and regulations of the SEC, has filed the Prospectus with the SEC pursuant to Rule 424(b). At the time the
Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Share Issuance Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the
requirements of the 1933 Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading. As of its date and at
the Share Issuance Date, the Prospectus complied and will comply in all material respects with the requirements of the 1933 Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to
be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.<B> </B>The Company was at the time of the filing of the Registration Statement eligible to use Form <FONT
STYLE="white-space:nowrap">S-3.</FONT> The Company is eligible to use Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act and it meets the transaction requirements as set forth in General Instruction I.B.1 of Form <FONT
STYLE="white-space:nowrap">S-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10. <U>Disclosure</U>. Except with respect to the material terms and conditions of the
transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided the Landlord or its agents or counsel with any information that it believes constitutes or might
constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information which is not otherwise disclosed in the Prospectus. The Company understands and confirms that the Landlord will rely on the foregoing representation in effecting
transactions in securities of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Representations and Warranties of the </U>Landlord. The Landlord hereby represents and
warrants to the Company that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1. <U>Organization and Existence</U>. The Landlord is a validly existing entity organized under the laws
of Delaware and has all requisite corporate power and authority to enter into and consummate the transactions contemplated by this Agreement and to carry out its obligations hereunder, and to receive the Shares pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2. <U>Authorization</U>. The Landlord has the requisite power and authority and has taken all requisite action necessary for, and no further
action on the part of the Landlord, its officers, managers or members is necessary for, (i)&nbsp;the authorization, execution and delivery of this Agreement and (ii)&nbsp;the authorization of the performance of all obligations of the Landlord
hereunder. This Agreement has been duly executed and delivered by the Landlord and, assuming </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
due authorization, execution and delivery by the Company, constitutes valid and binding obligations of the Landlord enforceable in accordance with their terms, except (a)&nbsp;as limited by
applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors&#8217; rights, (b)&nbsp;general principles of equity that restrict the availability of equitable remedies and
(c)&nbsp;to the extent that the enforceability of indemnification provisions may be limited by applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3. <U>No Conflicts</U>.
The execution, delivery and performance by the Landlord of this Agreement and the consummation by the Landlord of the transactions contemplated hereby will not (i)&nbsp;result in a violation of the organizational documents of the Landlord or
(ii)&nbsp;conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture
or instrument to which the Landlord is a party, or (iii)&nbsp;result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Landlord, except in the case of clauses
(ii)&nbsp;and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Landlord to perform its obligations
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Conditions to Share Issuance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1. <U>Conditions to the Landlord&#8217;s Obligations</U>. The obligation of the Landlord to accept the Shares at the Share Issuance is
subject to the fulfillment to the satisfaction of the Landlord on or prior to the Share Issuance Date of the following conditions, any of which may be waived by the Landlord: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall have performed in all material respects all obligations and covenants required to be performed by the Company pursuant to
the Transaction Documents as of the Share Issuance Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Shares shall have been registered under the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The representations and warranties made by the Company in <U>Section</U><U></U><U>&nbsp;3</U> hereof shall be true and correct in all
material respects as of the Share Issuance Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall have obtained any and all consents, permits, approvals,
registrations and waivers necessary for issuance of the Shares and the consummation of the other transactions contemplated by this Agreement, all of which shall be in full force and effect, including without limitation, notification of listing of
additional shares with Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or
magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the
consummation of the transactions contemplated hereby. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any
other governmental or regulatory body with respect to public trading in the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Company shall have delivered or caused
to be delivered to the Landlord the Prospectus (which may be delivered in accordance with Rule 172 under the 1933 Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Shares
shall be issued in book-entry form without any restrictive legend and shall not bear any stop-transfer instructions with the Company&#8217;s transfer agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) There shall have been no Material Adverse Effect with respect to the Company since the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2. <U>Conditions to Obligations of the Company</U>. The Company&#8217;s obligation to issue the Shares at the Share Issuance is subject to
the fulfillment to the satisfaction of the Company on or prior to the Share Issuance Date of the following conditions, any of which may be waived by the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Landlord shall have performed in all material respects all obligations and covenants required to be performed by the Landlord pursuant
to the Lease Termination Agreement and this Agreement as of the Share Issuance Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The representations and warranties made by the
Landlord in <U>Section</U><U></U><U>&nbsp;4</U> hereof shall be true and correct in all material respects as of the Share Issuance Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Landlord shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the acceptance of the
Shares by the Landlord and the consummation of the other transactions contemplated by this Agreement, all of which shall be in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court
or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated
hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory
body with respect to public trading in the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3. <U>Termination of Obligations to Effect Share Issuance; Effects</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The obligations of the Company, on the one hand, and the Landlord, on the other hand, under this Agreement shall terminate as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Upon the mutual written consent of the Company and Landlord; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Upon termination of the Lease Termination Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) By the Company if any of the conditions set forth in <U>Section</U><U></U><U>&nbsp;5.2</U> shall have become incapable of fulfillment,
and shall not have been waived by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) By the Landlord if any of the conditions set forth in
<U>Section</U><U></U><U>&nbsp;5.1</U> shall have become incapable of fulfillment, and shall not have been waived by the Landlord; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)
By the Landlord, if the Share Issuance has not occurred by the Share Issuance Date, unless such delay is caused solely by the Landlord. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>,
<U>however</U>, that, except in the case of clauses (i)&nbsp;and (ii) above, the party seeking to terminate its obligation to effect the Share Issuance shall not then be in breach of any of its representations, warranties, covenants or agreements
contained in this Agreement if such breach has resulted in the circumstances giving rise to such party&#8217;s seeking to terminate its obligation to effect the Share Issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Nothing in this <U>Section</U><U></U><U>&nbsp;5.3</U> shall be deemed to release any party from any liability for any breach by such party
of the terms and provisions of this Agreement or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event the Landlord terminates this Agreement pursuant to Section&nbsp;5.3(a)(iv) or (v), the Company shall pay to the Landlord, in
cash, an amount equal to $500,000.00 (representing the value of the Shares that would have been issued) within two (2)&nbsp;business days of such termination, by wire transfer of immediately available funds, in full satisfaction of the equity
issuance component of the Total Termination Amount (as defined in the Lease Termination Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1. <U>Successors and Assigns</U>. This Agreement may not be assigned by a party hereto without the prior written consent of the Company or
the Landlord, as applicable; <U>provided</U>, <U>however</U>, that the Landlord may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate without the prior written consent of the Company, provided such assignee
agrees in writing to be bound by the provisions hereof that apply to the Landlord. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Nothing in this
Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective permitted successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2. <U>Counterparts</U>. This Agreement may be executed in two (2)&nbsp;or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal
ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3. <U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4. <U>Notices</U>. All notices and
other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt, or (a)&nbsp;personal delivery to the party to be notified, (b)&nbsp;when sent, if sent by
electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient&#8217;s next business day, (c)&nbsp;five (5) days after having been sent by registered or certified mail, return
receipt requested, postage prepaid, or (d)&nbsp;one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall
be sent to the respective parties at their address as set forth below, or to such <FONT STYLE="white-space:nowrap">e-mail</FONT> address or address as subsequently modified by written notice given in accordance with this
<U>Section</U><U></U><U>&nbsp;6.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Seres Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">101
Cambridgepark Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: <U>[***]</U>; and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[***]
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy (which will not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">200 Clarendon Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Boston,
MA 02116 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Peter N. Handrinos; Wesley C. Holmes </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Landlord: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">BMR-SIDNEY</FONT> RESEARCH CAMPUS LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">4570 Executive Drive, Suite 400 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:
Legal Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: <U>[***]</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5. <U>Expenses</U>. The parties hereto shall pay their own costs and expenses in connection herewith regardless of whether the transactions
contemplated hereby are consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6. <U>Amendments and Waivers</U>. Any term of this Agreement may be amended and the observance of
any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Landlord. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7. <U>Severability</U>. Any provision of this Agreement that is prohibited or
unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be
enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by
applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.8. <U>Entire Agreement</U>. The Transaction Documents, including the signature pages thereto, together with the exhibits and schedules
thereto contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have
been merged into such documents, exhibits and schedules. In the event of any conflict, inconsistency or ambiguity between the terms of the Lease Termination Agreement and this Agreement with respect to the issuance, delivery, registration, sale or
transfer of the Shares, or the rights and obligations of the parties relating thereto, the provisions of this Agreement shall govern and control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.9. <U>Further Assurances</U>. The parties shall execute and deliver all such further instruments and documents and take all such other
actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.10. <U>Governing Law; Consent to Jurisdiction; Waiver of Jury Trial</U>. This Agreement shall be governed by, and construed in accordance
with, the internal laws of the Commonwealth of Massachusetts, without regard to the Commonwealth of Massachusetts&#8217; conflict of laws principles. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such
suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any
such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. <B>EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT
COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.</B><I> </I>If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Section&nbsp;6.11, the prevailing party in such Action or Proceeding shall be reimbursed by the <FONT STYLE="white-space:nowrap">non-prevailing</FONT> party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such Action or Proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.11. <U>Indemnification</U>. The Company shall indemnify and
hold harmless the Landlord and its Affiliates, and their respective members, managers, officers, employees, and agents, from and against any and all losses, claims, damages, liabilities, and expenses (including reasonable attorneys&#8217; fees)
arising out of or resulting from (a)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the Prospectus or the Prospectus Supplement or any document incorporated by reference therein, or
any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, (b)&nbsp;any failure of the Shares to be freely tradeable upon issuance as represented
herein, or (c)&nbsp;any breach by the Company of its representations, warranties, or covenants under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[remainder of page
intentionally left blank] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">COMPANY:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SERES THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Richard Kender</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Richard Kender</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Executive Chairman and Interim CEO</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Seres Therapeutics, Inc. &#8211; Share Issuance Agreement &#8211; Signature Page</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LANDLORD:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="white-space:nowrap">BMR-SIDNEY</FONT> RESEARCH CAMPUS LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Colleen O&#8217;Connor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Colleen O&#8217;Connor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: EVP, East Coast&nbsp;&amp; UK Markets</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Seres Therapeutics, Inc. &#8211; Share Issuance Agreement &#8211; Signature Page</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mcrb-20260731.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2610 Build:20260610.1 -->
<!-- Creation date: 8/4/2026 1:01:14 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:mcrb="http://serestherapeutics.com/20260731"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://serestherapeutics.com/20260731"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" namespace="http://xbrl.sec.gov/stpr/2025" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mcrb-20260731_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mcrb-20260731_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mcrb-20260731_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2610 Build:20260610.1 -->
<!-- Creation date: 8/4/2026 1:01:14 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mcrb-20260731_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2610 Build:20260610.1 -->
<!-- Creation date: 8/4/2026 1:01:14 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mcrb-20260731.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g133274g0804031743525.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g133274g0804031743525.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  0 .T# 2(  A$! Q$!_\0
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M\!6+IZ"1R/\ <%>.Y2IOFZ4W;Y-_Y6/TB-*CC8*A=<V-BI>DH17W7FIGKG[
MMM=:W\.O%7CZ_:1[OQEXBO-10R$G$*N411GH =]?._QY\=>(]7^._B7XR:-<
M32>&OAAK>G:((8V.R9-SBZZ<??;:?9Q7UM:3Q_LS?LBVS^7_ *3X=\.IB-1R
M]V4X&/>5_P!:^>?A9^RK\6=:_9Z.C#QCI&GZ3XMMFU.^TZ\L6><R7 #G>_\
M>^[],5M5A-TX48IW2OIWZ?C^1YF!Q&'6+Q.8U91C"4O9J]_@O[UK)Z\B2_[>
M/KKXA_#GPQ^T#X!M-.U=I[G0[MH=0A>TN'A9OERAW(0<8;IFOB_X&?LH^!?'
M?QL^,WAO55U673/"^HVUOIJ)J4R%$=7+!B&RW*CK7T!^P;XVOO$?P(M="UA)
M(M;\)W<NAW4<H(;$9_=GG_9(7_@!K&_9=@DB_:8_:0=XV1'U>S*LPP&^27I6
MLXTZ[I5''?\ R?ZG!AZN+RJGC\)3JM*FE:S_ +\5=>J_!D/_  4&F&B_"CP*
M4G:VA@\6Z<K/O(P@63.3Z8%9/A:UO/VTOC"OBV]:6'X0>$;MHM(LMQ4:Q>*?
MFGD ZH#C /; [MG;_P""AEHU[\,O!,2PF=3XPT_>@7<"N),Y'I7,6%Q>?L2_
M'(:5(DTOP<\:W1DM9%!9=&O6/S*?1#G\N?X345=*[YO@TO\ I\CHP7O95!4/
M]X_><OI[O-;^];;RO;6QT_\ P47FDMO@7H[12/$W_"36 RC%3C]YQ7>_MDRO
M!^RS\0Y(V9'72\AE."/G3O7!?\%%HY+OX$Z,($:8GQ+8-B,9X_><UWO[9,;3
M?LL_$-(U+NVEX"J,D_.E;5/BK?X5^IYN$M[++O\ K[+\Z9X'^P=\3M4\!:Y)
M\'/%]R[O=6<6N^'+N=C^_@GB$K1 G_>+ >H<>E>B_P#!/.:6?X):VTTCR./%
M&HC+L2>J<5P_QN^#^I:U^SA\*_B7X3C:'QSX&T73[Z(QK^\GMD@C:2,CJ=N"
MV/3<.]=C_P $XKF6\^ >I7<T#6SW7B.^N/*8$;=_EMC]:PH<T*L*4NB=O1V_
M(];-O8XG 8C'TK)SG%37:<>:[MVDK/UN>#_#+0OAU\9/B7X[L/C]J%\GQ!.L
M30V-IJ=Y+;00VP.(U@PP48.?; 7'>OO+Q'X@MOAIX5T406[7=K]KL-(B7S.0
MLLL<"L3SG&X'WQ7QM^U)\;O@]\9O#7B+PMI_A^^UKXFQRR6.G16VFR+=1W2/
MM5MX'*@C/4Y'2OI7PA\*];U;]GKP5X5\2:K-9>(].MM/GGO% E>.X@=)5!R?
MFP4"GGG%:8:T7*,+-]U^3\SESE2JTZ&(Q7-33=O9RV2LO>@OY7Z;]6>@Q^+E
MD^(%SX7^SD/#ID6I?:-W!#RR1[,>WEYS[UX-KO[:]EX5M[6YU/PO/<6][+<Q
MVRZ7="XE40S-$QF0+^[)*@@<Y&?2O4E^%FKIXGT_7U\7W U&*SCL;M_LBXNX
MDF>4 C=\I^<KQFM3P-\)_#_@?1?L$%E;W;M---)<SP*9)#)*\G)]C(0*[)*I
5+X=#YFE+ TM:L>?;1-KO?7UL?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g133274g0804031744665.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g133274g0804031744665.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  , *0# 2(  A$! Q$!_\0
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M$FZ[O@Y7[0([>-A9JW\._OZ@$=Z]M^,L2Z1XY^"]E9#[-:IKWDK%&<+L%M(
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M![3_ !%9>&I+ZUM];NFNY5>56\AB" (OE&U0#P#GH*:IR57FOHV_R)GC:-3
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.*S/G*LU4FYQ5D^G8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001609809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 31,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SERES THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-4326290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">101 Cambridgepark Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">945-9626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MCRB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d133274d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d133274d8k.htm">d133274d8k.htm</File>
    <File>mcrb-20260731.xsd</File>
    <File>mcrb-20260731_lab.xml</File>
    <File>mcrb-20260731_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d133274d8k.htm": {
   "nsprefix": "mcrb",
   "nsuri": "http://serestherapeutics.com/20260731",
   "dts": {
    "inline": {
     "local": [
      "d133274d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "mcrb-20260731.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mcrb-20260731_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mcrb-20260731_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-07-31_to_2026-07-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d133274d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-07-31_to_2026-07-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d133274d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://serestherapeutics.com//20260731/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-26-332742-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-332742-xbrl.zip
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M*'JZOMK3\5076J>[.:Y&4Y3Q79_>L/)0,OH%<ZO<86UZ*T <5J:2I=GTT/R
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MERJUD=WNM6GVY@@D*2KB\5!6.X/I!)H5U68* KX;$EU$Y;!:A%CD&33!A$=
M!^#JS-)F[?U;V6G.#:^-LYA:]:'6E/63]"VKT$'T(]!#"OM+B?A4DEOJAHS\
MJP;,MXB/+V^.EU8.OLSV41X5(ATPXO\,$M0+G<_=_B]O;7DQDV-0LU9)^SP6
M13U8* ]M-<"@ (ZXH,JA7\D !8%\IO(+"\CY>7<I85X*%_4\!Z$B(\,IL766
M?8(U#G=CIBODYE+;7!' >@ W<= ;<B/%73!&Q.ECNILJXK 1]TPMO$D>UEID
M\=V;V2LW#5)$]NX?F0QBW!K& :;X6$:/VS0KXM;ZL)PD:59[X2<9?340NS!
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MS0J [8!D@$$BBIXC&!75.FDV48DI?+Z A!Z+<?'VK&L8S4 R%2_=&*R85V\
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M_][>WM[.[M'>T>O];?-^@2UCX#+"A<CQ)%DY*K-G'$6&A&E"7>&1HCS'RWN
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MBYZSO<V0-#P1!#,AL2)".W1[7HS9P(\$%"BGR*W#\JY46M/OR<;41%4P4;B
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MR P1 48Z"]/@/C:PJVH;TT.UMN13N3NC1$7);V4B4'CT;H6.-L7 VBH4'+[
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MOWQ-(W:*"$.69["Z?*>"OCG!LF7QEM)T<8$6F 7''%8R<F8T42)WH^#;(Y7
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MTV]W^GH\YL&,% #S7O-VT*DE/WXIZCHN"]%MK0N$&8!&%ON-^$<[8>3PZR?
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MP/Q<<A573W'C@=XPX5A\)97ILA9T!)JQ"2?HK(Z'0J,GS%A\3F&""/ _$>#
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M$:FHX,>]8?^@!X1'(J9\=MQ;J2!4$:4]4$G(XY )3HY[&Z)Z']Z_?/'NNR"
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M/E<OY1V7>LO\WHE\%\U^^X+>\Q]02P,$%     @ 8Z $73$\0SNX!   @RH
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MDQ&6\5A:14UU(15]6C;GSK'I WK%Y3Z^P>NC4R'MB*M/:\>PQ7;A#+;UVC"
M*3.)BNR1)D=3*]=6%UJY7\OLO6/,\.9 JE2JO+1#K#!TY1R7^%57QB<B_$ZH
MJA/]CGT+^(-C@.\8A\=Y,@9U&LUM7=71;7NUG"X=XS2BRUZ,96 3MKY!?0VT
M@T&J3O"@\0W.9MTQG)TXQB+KS0O>)D-X&LK2 %7'6&K:(@S=1-C%MT]J)!?B
M50"WY8[@V[9LX;EV5[Y))?\>?U)])9^9V3U\#<&]&(Y@W/-M6;ISJU[(IR]U
M1OG?+#W]TK0\@B,<=UQ;BF?.4#3K24<!/85;45-=4D6?EHT[&R[FYQ#>GTEQ
MXDW"OJZZC/:]6D[N[+#\B?XR$%V9)'.QN4;6Q\(Z(*XNL0.&+39W-EF&DK.(
M94Q,'_#+6#%C[3AF9<KJ BMS:VFYLV/25V"F'.#54KZ);G[)5$^3R?'+XDL1
MJDOO)=>6HCO[*3O9]+2>@_KW+$OB.$.TQ/N&ZYD[&RM#B.;&8M@8CUC&C[Z4
MW-=5E]N^5\O)G=V3D:+F8:OA*AG+H[_N=D35);1CU.)Q9W_$3K';932C8@JG
M_%97KJTNK'*_EIEK^R"W":@ISKU/2BZR&:[O*14G/F]R($1U";YHVX+\'[9"
MKH*]TMQC@WE^<GW$_#-/ V++5U!+ 0(4 Q0    ( &.@!%VY",#,'Q4  .*#
M   .              "  0    !D,3,S,C<T9#AK+FAT;5!+ 0(4 Q0    (
M &.@!%V\$?W[VAP  ,Y[   1              "  4L5  !D,3,S,C<T9&5X
M,3 Q+FAT;5!+ 0(4 Q0    ( &.@!%W"!PUPL2X  &79   1
M  "  50R  !D,3,S,C<T9&5X,3 R+FAT;5!+ 0(4 Q0    ( &.@!%UI@IC2
MJ0H  '4M   0              "  31A  !D,3,S,C<T9&5X-3$N:'1M4$L!
M A0#%     @ 8Z $7:?'3;9M P  I0P  !$              ( !"VP  &UC
M<F(M,C R-C W,S$N>'-D4$L! A0#%     @ 8Z $71_(9Z):!@  NT,  !4
M             ( !IV\  &UC<F(M,C R-C W,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( &.@!%TQ/$,[N 0  (,J   5              "  31V  !M8W)B+3(P
D,C8P-S,Q7W!R92YX;6Q02P4&      < !P"] 0  'WL

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d133274d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mcrb-20260731.xsd" xlink:type="simple"/>
    <context id="duration_2026-07-31_to_2026-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001609809</identifier>
        </entity>
        <period>
            <startDate>2026-07-31</startDate>
            <endDate>2026-07-31</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-324">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-07-31_to_2026-07-31"
      id="Hidden_dei_EntityCentralIndexKey">0001609809</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-335">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-336">2026-07-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-337">SERES THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-338">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-339">001-37465</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-340">27-4326290</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-341">101 Cambridgepark Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-342">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-343">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-344">02140</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-345">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-346">945-9626</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-347">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-348">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-349">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-350">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-351">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-352">MCRB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-353">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-07-31_to_2026-07-31" id="ixv-354">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
